SNP - Sodium Nitroprusside
Phase 2Small molecule
SNP - Sodium Nitroprusside is one of 80 small molecule programs targeting Heart Failure. It is currently in Phase 2.
2
Indications
2
Total Trials
1
Active Trials
79
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
206 competitors in Heart Failure
#DrugCompanyPhaseTrials
1Brethine
SanofiPreclinical
Medrol
PfizerPreclinical
Amidate
PfizerPreclinical
Zemplar
AbbViePreclinical
Adriamycin
PfizerPreclinical
Savaysa
Daiichi SankyoPreclinical
Activase
RochePreclinical
Xifaxan
SSalix
Preclinical
SNP - Sodium Nitroprusside
UUniversity of Georgia
Phase 2
Xylocaine
MMEDRx USA, Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SNP - Sodium Nitroprusside. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- UUniversity of Georgia